(Q33398722)

English

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 (English)

1 reference

Europe PubMed Central

26 July 2017

phase II clinical trial

0 references

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Michael Leahy

5

0 references

Gedske Daugaard

object named as

Gedske Daugaard

9

0 references

author name string

Maria De Santis

1

1 reference

Europe PubMed Central

26 July 2017

Joaquim Bellmunt

2

1 reference

Europe PubMed Central

26 July 2017

Graham Mead

3

1 reference

Europe PubMed Central

26 July 2017

J Martijn Kerst

4

1 reference

Europe PubMed Central

26 July 2017

Pablo Maroto

6

1 reference

Europe PubMed Central

26 July 2017

Thierry Gil

7

1 reference

Europe PubMed Central

26 July 2017

Sandrine Marreaud

8

1 reference

Europe PubMed Central

26 July 2017

Iwona Skoneczna

10

1 reference

Europe PubMed Central

26 July 2017

Sandra Collette

11

1 reference

Europe PubMed Central

26 July 2017

Julie Lorent

12

1 reference

Europe PubMed Central

26 July 2017

Ronald de Wit

13

1 reference

Europe PubMed Central

26 July 2017

Richard Sylvester

14

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

12 December 2011

1 reference

Europe PubMed Central

26 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

26 July 2017

30

1 reference

Europe PubMed Central

26 July 2017

191-199

1 reference

Europe PubMed Central

26 July 2017

2

1 reference

Europe PubMed Central

26 July 2017

Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Overview of bladder cancer trials in the European Organization for Research and Treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Gemcitabine in transitional cell carcinoma of the urothelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Evidence-based management of cancer in the elderly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Carboplatin and urothelial tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

21 June 2018

Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

31 October 2018

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

31 October 2018

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

31 October 2018

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

31 October 2018

Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

31 October 2018

Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255563

31 October 2018

Carboplatin, Methotrexate and Vinblastin (Carbo-MV) for Advanced Urothelial Cancer A Phase II Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How many and which items of activities of daily living (ADL) and instrumental activities of daily living (IADL) are necessary for screening

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of cancer in the older person: a practical approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

General guidelines for the management of older patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22162575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.37.3571

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33398722&oldid=1536404715"